Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41992489
Repotrectinib's side effects, such as dizziness (58%), were manageable through dose adjustments and pharmacologic strategies, reducing severity in many patients.
Repotrectinib's side effects, like dizziness (58%) and dysgeusia (50%), were managed with dose modifications and pharmacologic interventions, reducing severity in many patients.
Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42015375
Liquid biopsy identifies resistance mutations in MET fusion-positive NSCLC, enabling effective therapy adjustment from type I to type II inhibitors when tissue biopsy is unfeasible.
Liquid biopsy aids in detecting MET resistance mutations in MET fusion-positive NSCLC, guiding therapy class-switch from type I to type II MET inhibitors.
Prognostic value of emotional distress in advanced non-small cell lung cancer: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42245743/
ED is significantly associated with poorer prognosis in patients with advanced NSCLC undergoing active anti-tumor therapies, contributing to both reduced short-term efficacy and diminished long-term survival. Further research should focus...
Systematic review and meta-analysis found that emotional distress in advanced NSCLC is associated with poorer treatment response, increased disease progression, and significantly reduced overall survival, underscoring the importance of psychosocial assessment and support.
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42201929/
The trial had been registered on ClinicalTrials.gov on Sep 30, 2022. ClinicalTrials.gov NCT05557552.
Phase II randomized trial suggests that reduced-dose thoracic radiotherapy combined with sequential chemo-immunotherapy may provide comparable progression-free survival with fewer severe adverse events than standard radiotherapy in older or frail unresectable stage III NSCLC patients unsuitable for concurrent chemoradiotherapy.
Right adrenal metastasis from left apical non-small cell lung carcinoma with contiguous tumor thrombus extending through the inferior vena cava into the right atrium - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42158028/
A 76-year-old male presented to our emergency department with intermittent exertional chest pain. Computed tomography of the abdomen and pelvis demonstrated a heterogeneous right adrenal mass measuring 7.7 cm with...
Case highlights rare NSCLC metastasis to the adrenal gland with contiguous tumor thrombus extending through the inferior vena cava into the right atrium, emphasizing distinctive imaging findings, aggressive disease behavior, and poor prognosis.